Article
Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra.
Seizure - 1 Feb 2022
Wang Qiu-Hong, Cao Jia-Jie, Wang Yang-Yang, Zhang Meng-Na, Liu Li-Ying, Wang Jing, Lu Qian, He Wen, Shen Yan-Wen, Chen Hui-Min, Luo Xiao-Mei, Chen Qian, Zou Li-Ping
Abstract excerpt
OBJECTIVE: Syntaxin binding protein 1 (STXBP1) plays an important role in the release of synaptic vesicles. STXBP1-related encephalopathy is a brain dysfunction caused by STXBP1 variation. Levetiracetam (LEV) exerts antiepileptic effects by binding to synaptic vesicle protein 2A (SV2A). This study aimed to analyze the prognosis of LEV treatment of STXBP1 encephalopathy (STXBP1-E) and the correlation among...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
